As shown in Figure 2 and 3, the pooled SMDs for alogliptin 12.5 mg treated vs controls, and alogliptin 25 mg treated vs controls demonstrated a significant reduction in HbA1c in patients treated with ...

Alogliptin is prescribed to reduce high blood sugar level in patients with type 2 diabetes along with diet control and exercise.

To assess potentially elevated cardiovascular risk related to new antihyperglycemic drugs in patients with type 2 diabetes, regulatory agencies require a comprehensive evaluation of the cardiovascular ...

SAN FRANCISCO, June 7 /PRNewswire/ -- Results from five pivotal phase 3 studies of alogliptin were announced today at the American Diabetes Association (ADA) 68th Scientific Sessions by Takeda Global ...

Alogliptin is an effective add-on to glimepiride therapy for improving glycemic control in Japanese patients with Type 2 diabetes, show study findings. Furthermore, the benefits of the combination ...

Takeda Pharmaceutical Co is going to have to wait a bit longer to market alogliptin after US regulators said they need more time to evaluate the Japanese drugmaker’s experimental type 2 diabetes drug.

Patients with type 2 diabetes and high cardiovascular risk due to recent acute coronary syndromes had similar rates of cardiovascular events when treated with the anti-diabetic agent alogliptin ...

Takeda is currently waiting for approval from the US Food and Drug Administration for SYR-322 (alogliptin) as a monotherapy. The drug was filed in January this year and if approved, it would be the ...

Background: Alogliptin is a new dipeptidyl peptidase (DPP-4) inhibitor, which is under investigation for treatment of type 2 diabetes either alone or in combination with other antidiabetic drugs. The ...

Alogliptin and Metformin combination is used along with diet and exercise to improve blood sugar control or to treat hyperglycemia in patients with type 2 diabetes. Self-care management in a diabetic ...